Clinical Effect Of Yishen Xiezhuo Jiedu Method Intervene The Renal Insufficiency(Phase 2-4)after Renal Cancer Operation

Objective:To observe the effect of Yishen xiezhuo jiedu method on the clinical symptom score and renal function of patients with renal insufficiency after operation(stage 2-4),and to evaluation its clinical efficacy.Method:Twenty patients who met the inclusion criteria were collected from patients who were admitted to a department of nephrology or urology at a hospital of Jiangsu Provincial Hospital between March 2016 and September 2017.After being enrolled in the group,it was given Yishen xiezhuo jiedu therapy and observed for 6 months.Clinical symptom scores and changes in renal function before and after treatment were compared.The SPSS21.0 statistical software was used to analyze and process the data,and the clinical efficacy of Yishen xiezhuo jiedu method in the treatment of patients with renal insufficiency(2-4 stage)after renal cell carcinoma was discussed.Results:1.Efficacy of syndromes:After 6 months of treatment,20 cases were clinically cured in 2 cases(10%),4 cases(20%)were markedly effective,12 cases(60%)were effective,and 2 cases(10%)were ineffective.The total effective rate of the syndrome is 90.00%.2.Clinical symptoms:The score of TCM syndrome before treatment is(20.60±2.76),and the score of TCM syndrome after 6 months of treatment is(8.30±4.46).Compared with that before treatment,the score of TCM syndrome of the patient after 6 months of treatment is presented.Downward trend,P<0.01,the difference was statistically significant;in the main symptoms of traditional Chinese medicine,"poor fatigue,shortness of breath,lazyness,poor appetite,weak backache,dry mouth,dry throat,five upsets,nausea,vomiting,and physical difficulty "Compared with before treatment,there was a statistically significant difference(P<0.01)after 6 months of treatment.3.Renal function:Before treatment,BUN(9.6213.30)mmol/L,after 2 months of treatment BUN(8.92±2.02),P>0.05,the difference was not statistically significant;Treatment of BUN(7.68±1.83)mmol/L,P<0.05,after 4 months,the difference is statistically significant;The difference was statistically significant for BUN(8.4912.11)mmol/L and P<0.05,after 6 months of treatment.Before the treatment,Scr(156.15±36.76)?mol/L,after 2 months of treatment,Scr(135.67±25.13)?mol/L,P<0.013 the difference was statistically significant;After 4 months of treatment,Scr(121.76±21.51)?mol/L,P<0.01,the difference was statistically significant;After 6 months of treatment,Scr(111.07±16.73)?mol/L,P<0.01,the difference was statistically significant.UA(443.19±90.30)?mol/L before treatment,UA(438.96±93.69)?mol/L,P>0.05 after 2 months of treatment,the difference was not statistically significant;After 4 months of treatment,UA(429.29±75.42)?mol/L,P>0.05,the difference was not statistically significant;After 6 months of treatment,UA(404.14±81.92)?mol/L,P<0.05,the difference is statistically significant.After 6 months of treatment,there were statistical differences between the three indicators.Conclusion:1.To improve the clinical symptoms of patients with renal insufficiency(2-4 stage)after renal carcinoma.2.To improve renal function in patients with renal insufficiency and to delay the rate of deterioration of renal function.